Zidovudine
- Generic Name
- Zidovudine
- Brand Names
- Combivir, Retrovir, Trizivir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 30516-87-1
- Unique Ingredient Identifier
- 4B9XT59T7S
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse tran...
- Indication
Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission
- Associated Therapies
- -
Safety of Reduced Dose Zidovudine (AZT) Compared With Standard Dose AZT in Antiretroviral-naïve HIV-infected Patients
- First Posted Date
- 2012-02-28
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- University Hospital, Geneva
- Target Recruit Count
- 136
- Registration Number
- NCT01540240
- Locations
- 🇨🇲
CNPS Hospital, Yaoundé, Cameroon
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2017-07-19
- Lead Sponsor
- Janssen-Cilag G.m.b.H
- Target Recruit Count
- 312
- Registration Number
- NCT01516970
Tocilizumab for KSHV-Associated Multicentric Castleman Disease
- Conditions
- Interventions
- First Posted Date
- 2011-09-27
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 8
- Registration Number
- NCT01441063
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- First Posted Date
- 2011-08-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 140
- Registration Number
- NCT01419561
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study of Options for Second-Line Effective Combination Therapy (SELECT)
- First Posted Date
- 2011-05-12
- Last Posted Date
- 2021-08-05
- Target Recruit Count
- 515
- Registration Number
- NCT01352715
- Locations
- 🇧🇷
Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil
🇲🇼University of North Carolina Lilongwe CRS (12001), Lilongwe, Malawi
🇿🇦Soweto ACTG CRS (12301), Johannesburg, South Africa
Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women
- Conditions
- Interventions
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 389
- Registration Number
- NCT00993031
- Locations
- 🇺🇬
Tororo District Hospital, Tororo, Uganda
A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents
- Conditions
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Tibotec Pharmaceuticals, Ireland
- Target Recruit Count
- 12
- Registration Number
- NCT00915655
Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-03-03
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 13
- Registration Number
- NCT00854581
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years
- Conditions
- Interventions
- First Posted Date
- 2008-12-01
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 54
- Registration Number
- NCT00799864
Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART
- Conditions
- Interventions
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2016-09-19
- Target Recruit Count
- 105
- Registration Number
- NCT00719602
- Locations
- 🇿🇲
George Clinic CRS (30273), Lusaka, Zambia
🇺🇬Makerere University - JHU Research Collaboration (30293), Kampala, Uganda
🇲🇼University of North Carolina Lilongwe (12001), Lilongwe, Malawi
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.